IP Library Granted Patent US 11,498,941
Granted Patent B2
US 11,498,941 · App. 16/629,609 · Granted Nov 15, 2022

Chromatography

Inventor: Michael Harry Rose (Slough, GB)
Assignee: UCB BIOPHARMA SRL
C07K1/22B01D15/1814B01D15/245B01D15/247B01D15/3809C07K1/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,498,941
App. No.
16/629,609
Granted
Nov 15, 2022
Kind
B2
Abstract

The present invention is in the field of purification and protein purification in particular. The invention provides improved techniques for the industrial-scale purification of proteins and other biomolecules. More specifically, it relates to a process for the purification of a compound of interest, such as a protein, preferably an antibody or an antibody fragment using a chromatography step, preferably a semi-continuous chromatography step.

Claims (39)

1. An industrial-scale process for purification of a product biomolecule from a feedstock comprising the product biomolecule and at least one impurity, the process comprising the steps of: a) loading feed from the feedstock to a chromatography matrix such that the product biomolecule binds to the chromatography matrix; b) eluting the product biomolecule from the chromatography matrix in an eluate by applying an elution solution to the chromatography matrix; wherein the eluate comprises: —a first fraction comprising purified product biomolecule; and—a second fraction comprising both the product biomolecule and at least one impurity, the second fraction comprising one or more leading and/or trailing fraction(s); and wherein the first fraction is collected separately from the second fraction; c) holding the second fraction in one or more container(s); d) loading the second fraction from the container(s) and additional feed from the feedstock to the chromatography matrix such that the product biomolecule in the second fraction binds to the chromatography matrix; wherein the additional feed is loaded simultaneously with or sequentially to the second fraction; and e) eluting the product biomolecule from the chromatography matrix in an eluate by applying an elution solution to the chromatography matrix, wherein the eluate comprises purified product biomolecule; wherein the chromatography matrix in step (a), step (b), step (d) and step (e) is the same chromatography matrix.

2. The process of claim 1 , wherein steps (b), (c) and (d) are repeated.

3. The process of claim 1 , wherein steps (b), (c) and (d) are performed at least twice.

4. The process of claim 1 , wherein the second fraction comprises (i) the leading fraction immediately preceding the first fraction; and/or (ii) the trailing fraction immediately following the first fraction.

5. The process of claim 1 , wherein:

steps (a) and (b) are repeated multiple times;

the second fractions collected in each step (b) are pooled together;

step (c) comprises holding the pooled second fractions in the container(s); and

step (d) comprises loading the pooled second fractions from the container(s) to the chromatography matrix such that the product biomolecule in the pooled second fractions binds to the chromatography matrix.

6. The process of claim 1 , wherein step (a) further comprises collecting flow-through containing unbound product biomolecule that does not bind to the chromatography matrix; and step (d) further comprises loading the flow-through to the chromatography matrix simultaneously with or sequentially to the second fraction and/or additional feed.

7. The process of claim 1 , further comprising processing the second fraction(s) to promote binding of the biomolecule to the chromatography matrix.

8. The process of claim 7 , wherein said processing takes place during step (c) and/or step (d).

9. The process of claim 7 , wherein said processing comprises altering the pH, ionic strength, concentration, temperature and/or solvent of the second fraction(s) and/or mixing and/or degassing the second fraction(s).

10. The process of claim 1 , further comprising testing the second fraction(s).

11. The process of claim 10 , wherein testing the second fraction(s) comprises determining one or more of the concentration of the product biomolecule; the concentration of impurities; the identity of impurities; the pH; the ionic strength; the temperature; the solvent; and/or the gas concentration of the second fraction(s).

12. The process of claim 1 , wherein step (c) comprises holding the second fraction(s) for at least 5 minutes.

13. The process of claim 12 , wherein the chromatography matrix is exchanged, cleaned or renewed during the hold time.

14. The process of claim 1 , wherein step (c) comprises holding the second fraction(s) overnight.

15. The process of claim 1 , wherein the product biomolecule is a protein, an antibody, an antibody fragment, a polynucleotide or a polypeptide.

16. The process of claim 1 , wherein the feedstock has a volume of at least 20 litres, optionally at least 100 litres.

17. The process of claim 1 , wherein the chromatography matrix has a bed volume of at least 4 litres.

18. The process of claim 1 , wherein in step (b) the volume of the eluate is at least 2 times the bed volume of the chromatography matrix, optionally wherein the volume of the eluate is between 2 times and 20 times the bed volume of the chromatography matrix.

19. The process of claim 1 , wherein the chromatography matrix is selected from:

an ion exchange chromatography matrix;

a hydrophobic interaction chromatography matrix;

an affinity chromatography matrix;

a mixed-mode chromatography matrix;

a chiral chromatography matrix; and

a dielectric chromatography matrix.

20. The process of claim 1 , wherein the chromatography matrix is in a chromatography column.

21. The process of claim 1 , wherein the chromatography matrix is a chromatography membrane or a monolith adsorber.

22. The process of claim 1 , wherein eluting the product biomolecule from the chromatography matrix is conducted at a flow rate of at least about 0.2 chromatography matrix volumes per minute.

23. The process of claim 1 , further comprising combining each of the first fractions.

24. The process of claim 1 , further comprising diafiltering and/or concentrating the purified product biomolecule.

25. The process of claim 1 , further comprising nanofiltering the purified product biomolecule.

26. The process of claim 1 , further comprising subjecting the purified product biomolecule to further chromatographic purification.

27. The process of claim 1 , further comprising chemically modifying the purified product biomolecule.

28. The process of claim 1 , further comprising formulating the purified product biomolecule with a pharmaceutically acceptable excipient, diluent or adjuvant.

29. A purified product biomolecule obtainable by the process of claim 1 .

Assignments (3)
CHANGE OF NAME Recorded Apr 3, 2020
From: UCB BIOPHARMA SPRL
To: UCB BIOPHARMA SRL
Reel/Frame 052315/0828 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2020
From: ROSE, MICHAEL HARRY
To: CELLTECH R&D LIMITED
Reel/Frame 052256/0708 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2020
From: CELLTECH R&D LIMITED
To: UCB BIOPHARMA SPRL
Reel/Frame 052256/0925 →
Priority Claims (1)
GB 1711481 · Jul 17, 2017 · national
Continuity (1)
Related Publication 20200331960A1 · Oct 22, 2020